EGFR and lung carcinoma: The elevation of CD109 promotes metastasis and drug resistance in lung cancer by activating the epidermal growth factor receptor (EGFR)–protein kinase B (AKT)–mammalian target of rapamycin (mTOR) signaling pathway [14].